Repatha (Evolocumab) Dose Adjustments for South Asian Patients
Evidence-based guide to evolocumab (Repatha) dosing considerations for South Asian patients, covering pharmacogenomics, cardiovascular risk profiles, and clinical trial subgroup data.
Ethnicity Evolocumab
4 source-based articles maintained by the HealthRX.com Editorial Team.
4articles
3topic areas covered
May 27, 2026latest review
Ethnicity Evolocumab library
Showing 4 of 4 clinical reviews.
Repatha East Asian Documented Efficacy Gaps: What the Trial Data Actually Show
A clinician-focused review of evolocumab (Repatha) efficacy, pharmacogenomics, and dosing considerations in East Asian patients, including FOURIER subgroup data, PharmGKB annotations, and population PK differences.
Repatha East Asian Dose Adjustments: What the Pharmacogenomic Data Actually Show
A clinician-focused review of evolocumab (Repatha) dosing in East Asian patients: what pharmacokinetic modeling, subgroup data, and regulatory labels support, what is plausible but unproven, and what still needs specialist or primary-source verification.
Repatha South Asian Safety Profile Differences: What Pharmacogenomics and Clinical Trials Show
A detailed clinical review of evolocumab (Repatha) safety, pharmacogenomics, and dosing considerations in South Asian patients, including FOURIER subgroup data, PCSK9 variant frequencies, and cardiovascular risk context.